Global Custom Market Research Reports Provider Company

phone

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

  • Published Date: 12 Jun 2018
  • Number of Pages: 101
  • Category: Pharmaceuticals
  • Country: Global
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 3, 1, 10, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Failure (Hepatic Insufficiency) - Overview
Liver Failure (Hepatic Insufficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
AVM Biotechnology LLC
Celgene Corp
Cell2B Advanced Therapeutics SA
Daewoong Co Ltd
Genentech Inc
Immune Pharmaceuticals Inc
MallInckrodt Plc
Martin Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
Novartis AG
PledPharma AB
Promethera Biosciences SA
Synlogic Inc
Takeda Pharmaceutical Co Ltd
Therapure Biopharma Inc
Unicyte AG
Versantis AG
Vital Therapies Inc
Liver Failure (Hepatic Insufficiency) - Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Failure and Alcoholic Hepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWSR-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enasidenib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ImmuneSafe - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipatasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTL-CEBPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resatorvid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silibinin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CYP3A4 for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYNB-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trimetazidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Failure (Hepatic Insufficiency) - Dormant Projects
Liver Failure (Hepatic Insufficiency) - Discontinued Products
Liver Failure (Hepatic Insufficiency) - Product Development Milestones
Featured News & Press Releases
May 14, 2018: PledPharma has completed the recruitment for the clinical trial with Aladote
Mar 29, 2018: Martin Pharmaceuticals Receives FDA Orphan Drug Designation for LIVANTRA
Mar 28, 2018: PledPharma receives European approval of the composition of matter patent for Aladote
Dec 12, 2017: Principal investigator James Dear presents Aladote as a potential new treatment for late stage liver toxicity after paracetamol overdose at Pharmacology conference
Dec 04, 2017: Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018
Oct 04, 2017: Principal investigator of Aladote study James Dear presents calmangafodipir as a potential new treatment for late stage liver toxicity after acetaminophen overdose at liver disease conference
Sep 14, 2017: The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group
Sep 06, 2017: Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors
Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure
Jun 08, 2017: First patient included in PledPharmas clinical trial with Aladote
Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
May 17, 2016: COMP Issued a Positive Opinion on Orphan Medicinal Product Designation for VS-01 for The Treatment of Acute Liver Failure
Feb 29, 2016: Versantis Receives Confirmation From The EMA that Its Application for Orphan Drug Designation in Acute Liver Failure Is Valid
Jan 31, 2016: Versantis Initiates the Manufacturing Scale Up of VS-01
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by AVM Biotechnology LLC, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Celgene Corp, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Daewoong Co Ltd, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Genentech Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by MallInckrodt Plc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Martin Pharmaceuticals Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Novartis AG, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Synlogic Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Therapure Biopharma Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Versantis AG, H1 2018
Liver Failure (Hepatic Insufficiency) - Pipeline by Vital Therapies Inc, H1 2018
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2018
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Liver Failure (Hepatic Insufficiency) - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018, provides an overview

View Report

Global Human Liver Model Market to reach USD 4.3 billion by 2025. Global Human Liver Model Market valued approximately USD 1.2 billion in 2016 is anticipated to grow with a

View Report

BioDelivery Sciences International Inc (BDSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports